Finch therapeutics ipo
WebApr 6, 2024 · According to analysts' consensus price target of $7.00, Finch Therapeutics Group has a forecasted upside of 1,777.2% from its current price of $0.37. Amount of … WebMar 19, 2024 · F inch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, raised $128 million by offering 7.5 million shares at $17, the high end of the range of $15 to $17. The...
Finch therapeutics ipo
Did you know?
WebMar 23, 2024 · About Finch Therapeutics. Finch Therapeutics is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical ... WebMar 19, 2024 · SOMERVILLE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company...
WebSusan E. Graf is Independent Chairman at Finch Therapeutics Group, Inc. In the past she held the position of Chief Executive Officer of Akamara Therapeutics, Inc., Chief Financial & Business Officer... WebMay 13, 2024 · Finch Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates May 13, 2024 PDF Version Completed upsized IPO, raising $130.8 million in gross proceeds Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2 2024
WebMar 18, 2024 · Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally … WebMar 1, 2024 · Change since IPO-98.16%: Recent News & Updates. Full year 2024 earnings: EPS and revenues miss analyst expectations ... Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome …
WebFeb 26, 2024 · Feb 26, 2024 04:35PM EST. Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public ...
WebApr 6, 2024 · Finch Therapeutics Group stock opened at $0.36 on Wednesday. The company’s 50-day moving average price is $0.42 and its two-hundred day moving average price is $0.84. The stock has a market cap... seth abrigoWebApr 5, 2024 · Finch Therapeutics Group. Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical … the things castWeb1月31日，Ouince Therapeutics裁员47%，以削减成本，并寻求骨靶向药物平台和精准骨生长分子对外授权，将资金用于扩大罕见病管道。 1月30日，Finch Therapeutics裁员95%，因临床注册速度缓慢，持续未经授权使用公司知识产权的有害影响，终止微生物组药物CP101的3期临床 ... the things celebritiesWebAug 8, 2014 · IPO上市: 2014-01-01: 医疗健康: 美国: Finch Therapeutics专注开发新型微生物疗法，为存在严重未满足医疗需求的患者提供服务。该新锐由麻省理工学院和OpenBiome的数据科学家、临床医生和微生物学家共同创立，采用创新的机器学习算法，基于高通量微生物分子数据 ... the things celebrity youtubeWebMar 19, 2024 · Finch’s shares are expected to begin trading on the Nasdaq Global Select Market on Friday, March 19, 2024 under the ticker symbol “FNCH.” The offering is … the things children sayWebApr 6, 2024 · A high-level overview of Finch Therapeutics Group, Inc. (FNCH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and … seth abshireWebApr 10, 2024 · Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2024. … the things channel